Company ProfilePremium

DAIHAN Scientific Co., Ltd.

Company Profile Analysis

Ticker: 131220.KQ주

ESOMAR 23 Corporate BadgeISO Certifications Badge
DAIHAN Scientific Co., Ltd. - Company showcase

Year Founded & Workforce

1980

114 Employees

DAIHAN Scientific Co., Ltd. logo

DAIHAN Scientific Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

DAIHAN Scientific Co., Ltd. Overview

DAIHAN Scientific is a Wonju-based, family-controlled small cap that combines two businesses most laboratory-equipment companies keep separate: it manufactures its own DAIHAN-brand general laboratory instruments (ovens, incubators, baths and circulators, stirrers, shakers, furnaces, freezers, autoclaves) and it acts as one of Korea's largest multi-brand distributors of third-party laboratory equipment and consumables to universities, government research institutes, corporate R&D centres, pharmaceutical companies and hospitals. Distribution dominates the revenue mix (about 81% merchandise versus 18% own products in Q2 2026) [S3]. The company has added a medical-device line (Daihan Medical: MFDS-certified ultra-low-temperature vaccine freezers, sterilisers, centrifuges, biosafety cabinets, mediclin™ consumables) and an IoT layer (Smart-Lab controllers, Wire app). Revenue reached KRW 81.1 billion in FY2025 with a 6.8% operating margin, a net-cash balance sheet and a 3–4% dividend yield, yet the shares trade at roughly 0.5x book, reflecting low growth visibility, heavy exposure to Korean public R&D budgets and sizeable minority interests in subsidiaries.


What the company does

DAIHAN Scientific operates as an integrated "total service" supplier to laboratories. Its own long-standing slogan, reproduced by distributor DKSH, is "Customer Oriented Total Service" [S10]. The business has three operating layers:

  1. Manufacturing (own products). At its Wonju production campus the company designs and builds general-purpose laboratory instruments under the DAIHAN brand. In 2012 the company stated annual production capacity of about KRW 30 billion and distribution capacity of about KRW 90 billion [S5, 2012]. Own products represented approximately 18% of revenue in Q2 2026 [S3].

  2. Distribution (merchandise). The company sources tens of thousands of SKUs from domestic and foreign manufacturers and sells them through direct sales, a national agency (dealer) network and logistics centres. In 2013 it reported about 30,000 products from roughly 170 manufacturers, sold through 45 agencies and 2 logistics centres [S5, 2013]. Later partner-network descriptions range from "about 270" manufacturers (DKSH brand page) to "more than 70 companies in 16 countries and 140 manufacturers in Korea" (KP International) [S10]. Merchandise represented approximately 81% of revenue in Q2 2026 [S3].

  3. Services and digital. The company provides installation, after-sales service, equipment rental (cited by its Algerian representative) and IoT-based laboratory monitoring through the DAIHAN Smart-Lab controller and the Wire app and web service for collecting, analysing and sharing experimental data [S9; S10]. A 90%-owned subsidiary, (주)대한랩서비스 (Daihan Lab Service), is consolidated [S1].

Company's own description

DART-derived summaries describe DAIHAN as a manufacturer, distributor and comprehensive service provider of research laboratory equipment and consumables [S9 via Investing.com; S15]. In 2025 press material the company described itself as Korea's first and largest integrated distributor, manufacturer and total-service provider of laboratory and medical equipment [S6].

Business model and revenue model

Revenue streamNatureApprox. shareSource / period
Merchandise (third-party products)Product resale; distribution margin81%S3, Q2 2026
Products (DAIHAN-manufactured)Own-brand manufacturing margin18%S3, Q2 2026
Other (services, rental, other)Service / rental1%S3, Q2 2026
Subscription / licensingNot reported as a separate stream; Wire app and Smart-Lab are bundled with hardware as far as disclosed0—

The model is overwhelmingly transactional product revenue. There is no disclosed recurring subscription or licensing revenue. Consumables (glassware, plasticware, mediclin™ medical consumables) provide some repeat purchasing; in 2013 glassware such as beakers and flasks was cited as only about 5% of sales [S5, 2013].

Value-chain position

DAIHAN sits at two points of the laboratory-equipment value chain simultaneously: as an OEM-brand manufacturer of mid-technology "general lab" instruments (temperature control, mixing, sterilisation), and as a channel intermediary between global or domestic instrument makers and Korean end users. Its distribution role gives it procurement relationships across most Korean public research institutions, which in turn creates a captive channel for its own-brand instruments.

Customer types and end-markets

Customer typeExamples of demandSource
Government organisations and public research institutesNational R&D programmes; equipment procurement via public tenderS9 (Morningstar); S1
UniversitiesTeaching and research laboratoriesS9; S7
Corporate R&D centresBio/nano materials, refining and chemicals, electrical/electronics/semiconductor researchS5, 2013
Pharmaceutical companiesQC and R&D laboratoriesS9
Hospitals and clinicsVaccine/blood freezers, sterilisers, centrifuges, biosafety cabinetsS6
Overseas distributors and institutional buyersVietnam, Indonesia, Egypt (military hospital tender), EuropeS6; S8

Independent characterisation

DAIHAN is best characterised as a domestic, budget-driven laboratory-supply distributor with a captive manufacturing arm. Revenue tracks Korean public and private R&D spending with a short lag (illustrated by the 2.7% revenue decline in FY2024, when the national R&D budget was cut to KRW 26.5 trillion, and the 13.1% rebound in FY2025 as the budget recovered to KRW 29.6 trillion) [S1; S11]. Gross margins in the high-20s percent reflect the distribution-heavy mix; operating margins have ranged from 3.6% to 10.0% over the past decade [S1]. The consolidated group includes several partially-owned sales subsidiaries, so a material share of consolidated profit (about 31% in FY2025) accrues to minority shareholders [S2].

Strategy

DAIHAN does not publish an investor-day presentation, medium-term plan or Corporate Value-Up Plan in the sources reviewed (contrast: peer Seoulin Bioscience filed a voluntary value-up plan on 21 Apr 2026 [S14]). Strategic themes below are drawn from company press statements and observed actions.

Stated strategic themes (paraphrased)

  1. "Customer Oriented Total Service" — one-stop procurement, manufacturing and service for laboratories [S10].

  2. Global DAIHAN — building an overseas subsidiary/franchise and distributor network to sell own-brand instruments worldwide (articulated 2015; continued via Vietnam, Indonesia, Egypt, MEDICA) [S8; S6].

  3. From lab-equipment leader to medical-device player — expanding GMP-certified medical devices and partnering with domestic and foreign specialists to broaden the medical line; building brand power in medical devices [S6].

  4. Smart laboratory / IoT — Smart-Lab System, Wire app, IoT-enabled cold chain [S8; S9; S6].

  5. Eco-friendly refrigeration — in-house refrigerant DH-MGR in freezers and refrigerators [S6].

Initiatives in the last 24 months

DateInitiativeTypeSource
2,024Indonesian distributor appointed (via KIMES 2024)Channel expansionS6
Mar 2025KIMES 2025 participation; GMP-certified devices showcasedMedical-device marketingS6
Mar 2025Egyptian military hospital ULT freezer tender win (6 units)ExportS6
Jun 2025Industry–academia cooperation agreement with Sangji UniversityPartnership / talentS7
Jul 2025Digital-healthcare social-contribution alliance MOU with Sangji UniversityESG / partnershipS7
Jul–Dec 2025Planned participation (directly or via distributors) at Medipharm Expo HCMC (Jul), Indonesia Hospital Expo (Oct), MEDICA Düsseldorf (Nov), Medipharm Expo Hanoi (Dec)Export marketingS6
Oct 2025Equipment donation (fume hood and two other items, KRW 27.2 M) to Sangji UniversityESGS7
Feb 2026Dividend more than doubled to KRW 125Capital returnS1

Cost programmes, transformation programmes, sustainability commitments with targets: none disclosed.

Guidance and medium-term targets

Management has not published revenue, margin or return targets in any source reviewed. No earnings guidance is provided.

Products & Services

Pricing is not publicly disclosed for any line; DAIHAN sells through quotation, public tender and distributor price lists. Launch years are not disclosed for most models. Specifications below are those published by DAIHAN's distributors or in company press material.

DAIHAN-manufactured laboratory instruments (Products, ~18% of revenue)

Product lineNamed models / brandsDescription and key capabilitiesTarget customerSource
Programmable tube furnacesFT-seriesEmbedded heating-element tube furnaces, maximum 1,000°C, digital PID programmable controlMaterials, chemistry and battery research labsS10 (DKSH)
Box/muffle furnacesFurnace rangeHigh-temperature ashing and heat treatmentMaterials, environmental labsS9
Refrigerated/heating bath circulatorsMaXircu™ CLDigital precise refrigerated and heating bath circulationChemistry, biology, QC labsS10
Chillers / cooling circulatorsMaXircu™ ChiRecirculating chiller for rotary evaporators, reactors and instrumentsChemistry, pharma labsS10
Water and oil bathsDigital high-temperature oil bath; water bathsConstant-temperature immersion bathsGeneral labsS10; S9
Laboratory freezersWLFDigital laboratory freezer, −35°C to +10°C, 420 L, with certificateBiology, pharma, hospitalsS10
Ultra-low-temperature freezersULT freezer (medical-certified variant)Vaccine, medicine and blood storage; MFDS medical certification (company-described as a Korean first); uses in-house eco-refrigerant DH-MGR; Smart-Lab IoT monitoringHospitals, vaccine programmes, biobanksS6
Medical refrigeratorsVaccine/pharmaceutical refrigeratorsCold-chain storage for vaccines and drugsHospitals, clinicsS6
Drying and heating ovensHi-Clean air ovens; forced-convection and natural-convection ovensDrying, curing, sterilising; clean-air variantsGeneral and semiconductor/electronics labsS10; S9
IncubatorsIncubator range (incl. CO2/BOD types as catalogued)Microbiology and cell-culture incubationLife-science labsS10; S9
Hotplates and hotplate stirrersAnalog and digital hotplate stirrersHeating plus magnetic stirringAll chemistry/biology labsS10
Magnetic stirrersMagnetic stirrer rangeMixing of chemical, laboratory and pharmaceutical materialsGeneral labsS10
Overhead stirrersHS-DHigh-speed digital overhead stirrer, up to 10/20 L, 200–3,000 rpm, digital feedback controlChemistry, process developmentS10 (KP International)
Shakers and vortex mixersOrbital/reciprocal shakers; vortex mixersSample agitationBiology, chemistry labsS9
HomogenizersHomogenizer rangeSample homogenisation and dispersionBiology, food, pharma labsS10
Heating mantlesHeating mantle rangeFlask heatingChemistry teaching and researchS9
Heating blocks / dry bath incubatorsDry-bath rangeTube heatingMolecular biologyS9
Autoclaves / sterilisersSteam autoclaves; dry-heat sterilisers; low-temperature plasma sterilisersLaboratory and medical sterilisation; multiple capacities including small-clinic sizesLabs, hospitals, clinicsS6; S9
CentrifugesClinical, general-purpose, high-speed refrigerated and micro-haematocrit centrifugesMicro- and macro-tube rotorsHospitals, researchS6; S9
Biological safety cabinetsBSC rangeOperator and sample protection for infectious-agent workHospitals, virology labsS6
Fume hoods and reagent storageFume hoods; filtering reagent cabinets; safety cabinets for corrosive/flammable reagentsLaboratory safety and chemical storageAll labs; universitiesS6; S7
Desiccator cabinetsDesiccator rangeMoisture-free storageGeneral labsS9
Ultrasonic cleanersUltrasonic cleaner range (CE certified)Removal of dirt, grease, waxes and oil from lab wareGeneral labsS10
Evaporators and reactorsEvaporator and reactor rangeSolvent evaporation, synthesisChemistry, pharmaS9
Freeze-dry systemsFreeze-dryer rangeLyophilisationPharma, food, biologyS9
Glass/labware washersLabware washer rangeAutomated washingLarger labsS9
Water purificationWater purification productsLab-grade waterAll labsS9
Balances and moisture analysersAnalytical balance; moisture analyserWeighing and moisture determinationQC, general labsS10
Mills, viscometers, magnifiers, gel documentationVariousSample preparation and analysisGeneral labsS9

Brand architecture: Investing.com describes smart-lab and touch-screen systems sold under the "Wisd" brand [S9]; DAIHAN catalogues have historically used "Wise"-prefixed product family names (for example for stirrers, thermal equipment and circulators).

Digital / smart-laboratory offerings

OfferingDescriptionLaunchSource
DAIHAN Smart-Lab System / controllerInstrument controller with experiment data recording, storage management and self-diagnostics; mobile remote controlFirst shown at ACHEMA 2012S8; S9
Wire app and web serviceCollection, analysis and sharing of experimental data from connected instruments—S9
IoT-enabled cold chainSmart-Lab monitoring applied to medical freezers and refrigerators—S6

Daihan Medical (medical devices and consumables)

ProductDescriptionRegulatory statusSource
Ultra-low freezers for vaccines/medicines/bloodEco-refrigerant DH-MGR; IoT monitoringMFDS medical certificationS6
Medical refrigeratorsVaccine and drug storageNot specifiedS6
Sterilisers (dry heat, high-pressure steam, low-temperature plasma)Multiple capacities for hospitals and small clinicsGMP-certified devices exhibitedS6
Centrifuges (clinical, high-speed refrigerated, micro-haematocrit)Micro/macro tubesGMP-certified devices exhibitedS6
Biosafety cabinets, fume hoods, filtering reagent cabinets, safety cabinetsLaboratory safety for medical researchNot specifiedS6
mediclin™ sample containersKorean-made PP containers, sterile and non-sterileNot specifiedS6
mediclin™ slide glass and cover glassMicroscopy consumablesCE certifiedS6
Stainless-steel instrumentsMedical and laboratory instrumentsNot specifiedS6

The company stated in March 2025 that Daihan Medical Division revenue was growing strongly each year, but no figures were disclosed [S6].

Distributed third-party merchandise (~81% of revenue)

DAIHAN's distribution catalogue spans general lab equipment, analytical instruments, plasticware, glassware, chemicals-adjacent consumables and safety products from domestic and international manufacturers. Specific principal brands and exclusive distributorships are not named in the sources reviewed. The company referenced supply and alliance agreements with advanced North American and European lab-equipment makers in FY2011 [S5].

Services

ServiceDescriptionSource
Total service (installation, after-sales)Integrated procurement-to-service offering for labsS10; S6
Equipment rentalCited by overseas representativeS10
Laboratory servicesVia 90%-owned Daihan Lab ServiceS1

Financial Narrative

All figures K-IFRS consolidated, KRW billion unless noted. Primary sources: S1 (DART business reports compiled by ETF Shopping) for FY2021–FY2025 income-statement totals, EPS and dividends; S2 (Valueline) for FY2022–FY2025 balance sheet and FY2025 line items.

Income statement

Notes: (1) FY2025 EBITDA (KRW 7.16 billion), pre-tax income (KRW 5.65 billion), tax (KRW 0.88 billion), controlling and NCI net income are from S2. (2) EPS discrepancy: S1 reports FY2025 basic EPS of KRW 478; S2 reports KRW 440. S2's controlling net income of KRW 3.28 billion divided by ~7.45 million issued shares implies ~KRW 440; dividing by ~7.2 million outstanding (ex-treasury) shares implies ~KRW 455. The DART figure should be checked directly. (3) Diluted EPS: no dilutive instruments were identified (no convertible bonds or warrants on the balance sheet per S2), so diluted EPS is expected to equal basic EPS; not separately confirmed.

Revenue CAGR: FY2021–FY2025: 5.2% per year (KRW 66.3 billion to 81.1 billion). FY2016–FY2025: 6.5% per year (KRW 46.1 billion to 81.1 billion) [S1].

Ten-year revenue and operating income context

Source: S1, DART business reports FY2016–FY2025: ### Quarterly trajectory

Source: S1, DART quarterly/half-year/business reports, filed 16 May 2024 to 14 Aug 2026.

H1 2026 summary: revenue KRW 39.2 billion (+13.0% vs. KRW 34.7 billion in H1 2025); operating income KRW 3.1 billion (+19% vs. KRW 2.6 billion); net income KRW 2.8 billion (vs. KRW 2.2 billion) [S1, analyst aggregation of quarterly figures]. Trailing-twelve-month revenue to June 2026: KRW 85.6 billion; TTM operating income KRW 5.95 billion; TTM EBITDA KRW 7.71 billion [S2].

Balance sheet

Sources: S2 (FY2022–FY2025 line items); S1 (FY2021 cash and total liabilities). Total borrowings exclude "short-term financial liabilities" of KRW 3.8 billion (FY2025), whose composition (likely lease and other financial liabilities) is not detailed in S2.

Balance sheet at 30 June 2026: total assets KRW 73.1 billion; cash KRW 3.4 billion; short-term financial assets KRW 12.5 billion; inventories KRW 28.2 billion (merchandise KRW 15.4 billion, products KRW 5.9 billion, raw materials KRW 5.1 billion); trade receivables KRW 8.1 billion; borrowings nil; total liabilities KRW 14.7 billion; equity attributable to owners KRW 46.1 billion; NCI KRW 12.4 billion; total equity KRW 58.4 billion; BVPS KRW 6,180.

Revaluation: a land revaluation surplus rose from KRW 2.26 billion (FY2023) to KRW 3.89 billion (FY2024), coinciding with land carrying value rising from KRW 6.09 billion to KRW 8.15 billion; FY2024 other comprehensive income included a KRW 1.63 billion revaluation gain [S2]. This flatters FY2024 equity growth relative to retained earnings.

Cash flow

Sources: S2 for FY2025 cash-flow items (OCF KRW 5.44 billion; PP&E purchases KRW 0.31 billion; D&A KRW 1.77 billion; consolidated dividends paid KRW 0.69 billion; LTD repayment KRW 1.20 billion); S1 for dividends declared and treasury purchases FY2021–FY2025. S1 reports FY2025 FCF of KRW 5.1 billion; S2 reports KRW 5.21 billion on its own definition.

Trailing twelve months to June 2026: OCF KRW 5.20 billion; PP&E purchases KRW 0.47 billion; FCF KRW 4.30 billion; consolidated dividends paid KRW 1.31 billion (reflecting the higher FY2025 dividend paid in April 2026).

Ratios

All ratios are analyst calculations from S1/S2 data using closing balances. ROIC uses an FY2025 effective tax rate of 15.6% (tax KRW 0.88 billion / pre-tax KRW 5.65 billion). Third-party published ratios: S1 reports ROE 8.4%, ROA 6.6%, payout 26–28%; S2 reports TTM ROE 7.75%.

Commentary on trends, inflections and drivers

Revenue. DAIHAN has compounded revenue at roughly 5–7% per year for a decade, with only two down years (FY2017, −10.2%; FY2024, −2.7%) [S1]. The FY2024 contraction coincided precisely with the Korean government's 2024 R&D budget cut to KRW 26.5 trillion (down from KRW 29.3 trillion-plus in 2023 per Newsis's 9.4% decline figure) [S11]. The FY2025 rebound of 13.1% to a record KRW 81.1 billion, and continued 12–14% quarterly growth through Q2 2026, track the partial restoration of the budget to KRW 29.6 trillion in 2025 and its further expansion to roughly KRW 35.3–35.5 trillion for 2026 [S1; S11]. The company's own statements also point to growth in the Daihan Medical division and export orders [S6].

Margins. Gross margin peaked at 30.1% in FY2023 and has since settled at 27.7% for two years [S1]. The FY2024 compression was primarily operating deleverage: gross profit fell KRW 2.3 billion on flat SG&A. In FY2025, gross profit recovered but SG&A rose 7.6% to KRW 16.9 billion, so operating margin only partially recovered to 6.8%, still well below the FY2022 peak of 10.0%. Personnel costs are a growing burden: standalone payroll reached KRW 5.93 billion (12.6% of standalone revenue) in FY2025, up from 10.9% in FY2021, with average pay rising 16.6% between FY2021 and FY2025 [S1]. Foreign-exchange losses (KRW 0.73 billion) exceeded FX gains (KRW 0.47 billion) in FY2025 [S2], consistent with the import-heavy merchandise mix.

Quarterly volatility. Q4 is the largest revenue quarter (year-end public procurement), but Q4 2025 operating profit fell 54% YoY to KRW 0.6 billion on record revenue of KRW 25.2 billion [S1]. The cause is not disclosed in the sources reviewed; possibilities include year-end bonus accruals, inventory write-downs or a lower-margin project mix. This is a key monitorable.

Minority leakage. About 31% of FY2025 consolidated net income (KRW 1.49 billion of KRW 4.77 billion) belonged to non-controlling shareholders of subsidiaries [S2]. Valuation multiples should therefore be measured on owners' earnings and owners' equity.

Balance sheet. The company is effectively debt-free (KRW 0.2 billion borrowings at FY2025; nil at June 2026) with KRW 16.1 billion of cash and short-term financial instruments at FY2025 [S2]. Net cash has more than doubled since FY2022. However, inventory is the largest asset (35% of total assets at FY2025) and rose a further 11% to KRW 28.2 billion in H1 2026, while cash fell to KRW 3.4 billion at June 2026, partly reflecting the doubled dividend paid in April [S2].

Working capital and cash conversion. The cash conversion cycle is long at ~169 days, driven by ~158 days of inventory [analyst calculation from S2]. DSO lengthened from 29 to 40 days between FY2022 and FY2025 as receivables jumped 38% in FY2025 on Q4 revenue concentration. FY2025 OCF of KRW 5.4 billion nonetheless exceeded net income, helped by D&A of KRW 1.8 billion and minimal capex (KRW 0.3 billion), giving a FCF yield of roughly 20% on market capitalisation.

Capital returns. DPS was flat at KRW 60 for seven years (FY2018–FY2024) before more than doubling to KRW 125 for FY2025 [S1]. Treasury purchases of KRW 0.5–1.0 billion were made in 2018, 2020, 2022, 2023 and 2024 but none in 2025 [S1]. Total shareholder returns in FY2025 were about 28% of owners' net income [S1].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue type

Revenue typeContentsShare of revenue (%) Q2 2026Source

Merchandise (상품)

Third-party lab equipment, analytical instruments, consumables, medical supplies

81

S3

Products (제품)

DAIHAN-manufactured instruments (temperature control, mixing, sterilisation, freezers, safety cabinets)

18

S3

Other (기타)

Services, rental, other

1

S3

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Total revenue (KRW Bn)

73.771.781.1

Total revenue YoY growth (%)

2.0-2.713.1

Revenue by Segment

MetricFY2025

Consolidated revenue (KRW Bn)

81.1

Standalone (parent) revenue (KRW Bn)

47.0

Implied subsidiary contribution before eliminations (KRW Bn)

34.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityDAIHAN stake (%)Total assets (KRW Bn)Net income (KRW Bn)Inferred roleSource / period

DAIHAN VIETNAM CO., LTD.

50.064.00.25

Vietnam sales/distribution

S1, latest FY

(주)싸이랩코리아 (Sci-Lab Korea)

37.7817.31.48

Domestic lab-supply affiliate; also holds 7.95% of DAIHAN

S1, latest FY

(주)올포랩 (AllforLab)

73.53.420.17

Domestic lab-supply sales

S1, latest FY

(주)대한과학대구경북지사 (DAIHAN Daegu-Gyeongbuk branch company)

50.24.310.62

Regional sales company

S1, latest FY

(주)대한랩서비스 (Daihan Lab Service)

90.00.240.025

Laboratory services

S1, latest FY

㈜올랩 (Allab)

50.51.440.27

Domestic sales

S1, latest FY

(주)대한분석기기 (Daihan Analytical Instruments)

51.00.240.003

Analytical-instrument sales

S1, latest FY

DAIHAN Scientific Europe B.V.

———

European franchise entity (established 2015); current status not confirmed

S8

“—” = not publicly disclosed.

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

66.372.373.771.781.1

Revenue growth (%)

7.89.12.0-2.713.1

Cost of sales (KRW Bn)

47.850.751.551.858.7

Gross profit (KRW Bn)

18.421.622.219.922.5

SG&A (KRW Bn, gross profit minus operating income)

12.514.416.015.716.9

Operating income (KRW Bn)

5.97.26.24.25.5

EBITDA (KRW Bn)

————7.2

Pre-tax income (KRW Bn)

————5.7

Income tax (KRW Bn)

————0.9

Net income, total (KRW Bn)

5.06.25.23.94.8

Net income attributable to owners (KRW Bn)

————3.3

Net income attributable to NCI (KRW Bn)

————1.5

EPS basic (KRW, S1)

524657543386478

Dividend per share (KRW)

60606060125

Gross margin (%)

27.829.830.127.727.7

Operating margin (%)

8.810.08.45.96.8

EBITDA margin (%)

————8.8

Net margin (%)

7.68.67.15.55.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (FY2016–FY2025)

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

46.141.447.155.261.566.372.373.771.781.1

Operating income (KRW Bn)

1.61.92.62.23.65.97.26.24.25.5

Net income (KRW Bn)

2.21.32.51.92.85.06.25.23.94.8

Operating margin (%)

3.64.75.54.05.98.810.08.45.96.8

EPS (KRW)

255142242165229524657543386478

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

13.917.618.421.715.719.021.225.217.621.6

Operating income (KRW Bn)

0.80.91.21.30.91.72.30.61.02.1

Net income (KRW Bn)

0.80.91.21.10.81.42.40.20.91.9

Revenue YoY (%)

————12.97.915.016.012.113.8

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

—59.564.067.872.2

Current assets (KRW Bn)

—39.044.447.052.8

Cash and cash equivalents (KRW Bn)

5.75.15.75.45.0

Short-term financial instruments (KRW Bn)

—5.17.18.011.1

Trade receivables (KRW Bn)

—5.86.36.59.0

Inventories (KRW Bn)

—21.523.425.225.4

Property, plant and equipment (KRW Bn)

—18.517.819.017.9

Goodwill (KRW Bn)

—0.00.00.00.0

Other intangibles (KRW Bn)

—0.30.20.20.1

Short-term borrowings incl. current portion of LTD (KRW Bn)

—0.12.51.50.2

Long-term borrowings (KRW Bn)

—2.50.00.00.0

Total borrowings (KRW Bn)

—2.62.51.50.2

Net debt, borrowings less cash and ST financial instruments (KRW Bn)

—-7.5-10.3-11.8-15.9

Total liabilities (KRW Bn)

16.015.015.314.915.4

Equity attributable to owners (KRW Bn)

—36.439.242.245.0

Non-controlling interests (KRW Bn)

—8.09.510.711.8

Total equity (KRW Bn)

—44.448.752.956.8

Working capital (KRW Bn)

—27.029.733.338.5

Book value per share (KRW)

—4,8875,2585,6646,033

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

————5.4

Capital expenditure, PP&E and intangibles (KRW Bn)

————0.3

Free cash flow (KRW Bn)

————5.1

Depreciation and amortisation (KRW Bn)

————1.8

Dividends declared by parent (KRW Bn)

0.40.40.40.40.9

Dividends paid, consolidated incl. to NCI (KRW Bn)

————0.7

Treasury share purchases (KRW Bn)

0.00.50.51.00.0

Repayment of long-term borrowings (KRW Bn)

————1.2

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025

ROE, total NI / closing total equity (%)

14.010.77.48.4

ROE, owners' NI / closing owners' equity (%)

———7.3

ROA, total NI / closing total assets (%)

10.48.15.86.6

ROIC, NOPAT / (equity + debt − cash and ST investments) (%)

———11.4

Current ratio (x)

3.273.023.433.68

Total borrowings / total equity (%)

5.95.12.90.3

Total liabilities / total equity (%)

33.831.428.227.2

Net debt / EBITDA (x)

———-2.2

Interest coverage, EBIT / interest expense (x)

———138

Asset turnover, revenue / closing assets (x)

1.221.151.061.12

Days sales outstanding

29.431.233.040.4

Days inventory outstanding

154.4166.1177.6157.9

Days payables outstanding

34.837.032.429.6

Cash conversion cycle (days)

149.0160.3178.2168.7

Dividend payout, parent dividends / owners' NI (%)

———27

Revenue by Region and Revenue by Region (%)

RegionFY2025TTM Jun 2025TTM Sep 2025TTM Mar 2026TTM Jun 2026

Domestic revenue (KRW Bn)

72.366.968.474.276.3

Export revenue (KRW Bn)

8.88.09.28.89.4

Total revenue (KRW Bn)

81.174.977.683.085.6

Export share (%)

10.910.711.910.610.9

Country / Region Details

Country / regionEvidence of activitySource

Republic of Korea

~89% of revenue; national agency network

S2; S5

Vietnam

50.06%-owned subsidiary DAIHAN VIETNAM; Vietnamese distributor exhibiting at Medipharm Expo (Ho Chi Minh City, Jul 2025); company participation planned at Medipharm Expo Hanoi (Dec 2025)

S1; S6

Indonesia

Distributor agreement signed via KIMES 2024; distributor exhibiting at Indonesia Hospital Expo, Jakarta (Oct 2025)

S6

Egypt

Tender win: six ultra-low freezers for a military hospital (reported Mar 2025)

S6

Germany / Europe

MEDICA Düsseldorf participation planned (Nov 2025); DAIHAN Scientific Europe B.V. (2015); ACHEMA exhibitor 2012 and 2015

S6; S8

Algeria

Represented by SARL KP International

S10

Southeast Asia (DKSH territories)

DAIHAN brand catalogued by DKSH Technology

S10

US, China, Turkey, Malaysia

Overseas subsidiaries/franchise entities cited in 2015

S8

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

6,8406,2804,6304,810

Year-end market cap (KRW Bn)

51.046.834.535.9

P/E on year-end price (x)

———10.9

P/B on owners' equity (x)

—1.190.820.80

Performance Window to 20 Oct 2026 Details

Performance window to 20 Oct 2026 (price KRW 3,430)Return (%)Source

1 month

-4.2

S1

6 months

-28.4

S1

Year to date (vs. KRW 4,810 at end-2025)

-28.7

Analyst calc. from S2

1 year

-28.5

S1

Since end-2023 (~2.8 years)

-45.4

Analyst calc. from S2

Since end-2022 (~3.8 years)

-49.9

Analyst calc. from S2

Valuation Multiples

MultipleDAIHANBasisSeoulin BioscienceSource

P/E (TTM)

7.2x

Price / TTM EPS

44.95x

S1; S2; S14

P/B

0.56x (owners' equity) / 0.45x (S1 basis)

Jun 2026 equity

0.49x

S2; S1; S14

EV/Sales (TTM)

0.26x

EV KRW ~22.0 B incl. NCI, less cash and ST investments

—

Analyst calc. from S2

EV/EBITDA (TTM)

2.9x

TTM EBITDA KRW 7.71 B

—

Analyst calc. from S2

Price / FCF (FY2025)

~5.0x

FCF KRW 5.1 B

—

S1

Dividend yield

3.61%

FY2025 DPS KRW 125

2.26%

S1; S14

Per-Share Data and Dividends & Capital Returns

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Dividend per share (KRW)

405060606060606060125

Total dividends declared (KRW Bn)

0.30.40.40.40.40.40.40.40.40.9

Treasury purchases (KRW Bn)

0.00.01.00.00.30.00.50.51.00.0

Total shareholder return / NI (%)

13358136441220255428

Capital Markets

ItemStatusSource

Moody's / S&P / Fitch

Not rated

—

Domestic ratings (KIS, NICE, Korea Ratings)

No public bond ratings identified (company has no bonds outstanding)

S2

Debt maturity profile

No borrowings at 30 Jun 2026; KRW 1.2 B long-term loan repaid in FY2025

S2

Analyst Conclusions

Management guidance

None published.

Growth expectations

No consensus exists. As a reference point, the H1 2026 run-rate (revenue +13.0% YoY) and a national R&D budget up ~19% for 2026 imply FY2026 revenue growth in the low-teens if H2 follows H1; at a flat 6.8% operating margin this would equate to FY2026 revenue of roughly KRW 91–92 B and operating income of about KRW 6.2 B. This is an illustrative analyst scenario, not a forecast or company guidance.

Bull case

  1. Budget-driven volume tailwind. The 2026 R&D budget of KRW 35.3–35.5 T is ~33% above the 2024 trough; DAIHAN's revenue has historically moved with budgets (−2.7% in FY2024, +13.1% in FY2025, +13% in H1 2026) [S1; S11].

  2. Deep value with downside protection. At ~0.5x book, ~2.9x EV/EBITDA and ~5x price/FCF, the market prices DAIHAN as ex-growth despite record revenue; net cash and short-term investments of KRW 16.0 B at June 2026 equal ~62% of market cap [S2; S1].

  3. Capital-return and governance optionality. The doubled dividend, rising insider stake and Korea's value-up / dividend-tax reforms could drive re-rating, particularly if the company simplifies its subsidiary structure or raises payout further [S1; S4].

Bear case

  1. Margin ceiling. Despite record revenue, FY2025 operating margin (6.8%) remained well below FY2022 (10.0%); Q4 2025 operating profit fell 54% on record sales, and wage and FX pressures persist [S1; S2].

  2. Working-capital drag and cash decline. Inventory rose to KRW 28.2 B and cash fell to KRW 3.4 B by June 2026; a ~169-day cash conversion cycle consumes much of the growth in profit [S2].

  3. Structural value leakage. ~31% of consolidated profit goes to minority holders in subsidiaries; reciprocal shareholding with Sci-Lab Korea and family control limit the likelihood of minority-friendly restructuring; no analyst coverage or IR limits rerating catalysts [S1; S2; S15].

Catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorableWhy it matters
~Mid-Nov 2026Q3 2026 quarterly reportConfirms whether 12–14% growth and operating leverage persist
Dec 2026National Assembly approval of 2027 R&D budgetSets FY2027 demand
~Feb 2027FY2026 dividend decisionTests whether KRW 125 DPS is a new floor
~Mar 2027FY2026 business report; Q4 marginQ4 profitability was weak in FY2025
Mar 2027KIMES 2027 participation; medical export ordersEvidence of medical-device scale-up
OngoingInventory and cash levelsWorking-capital discipline
OngoingIdentity and purpose of 2026 large-shareholding filingsPotential control or activism signal
OngoingAny value-up plan, treasury-share cancellation or subsidiary restructuringRe-rating triggers

Analyst verdict

DAIHAN Scientific is a sound but unremarkable business trading at a remarkable discount. Operationally, the company has done what its model allows: it compounded revenue at about 6.5% per year over FY2016–FY2025, kept the balance sheet debt-free, and responded to the 2025–2026 restoration of Korea's national R&D budget with five consecutive quarters of double-digit revenue growth, culminating in a record KRW 81.1 billion in FY2025 and a further 13% increase in H1 2026. The dual manufacturer-distributor structure, a broad supplier network and medical certifications give it a defensible niche in Korea's general-laboratory market.

The constraints are equally clear. Distribution economics cap gross margin in the high-20s percent; R&D at ~1.4% of revenue limits product differentiation against global brands; and a long cash conversion cycle absorbs much of the incremental profit. Operating margin has not recovered to the FY2022 peak, and the weak Q4 2025 raises questions about cost control at the busiest point of the year. Roughly a third of consolidated earnings belongs to minority shareholders in subsidiaries, and the founder family, together with a reciprocal-shareholding affiliate, controls 37% of the votes.

At KRW 3,430, the market values the company at about 0.5x book, under 3x EV/EBITDA and roughly 5x free cash flow, with a 3.6% dividend yield. Much of this discount is structural (illiquidity, family control, no coverage, budget dependency) rather than a mispricing of current earnings. A re-rating requires a visible catalyst: sustained margin expansion above 8%, a formal shareholder-return policy, treasury-share cancellation, or a simplification of the subsidiary structure. Absent these, DAIHAN is best viewed as a cash-rich, budget-cyclical income stock whose earnings are set to benefit from the 2026 R&D upcycle, with limited downside on asset value but uncertain upside on multiple.


Data limitations. DART primary documents could not be accessed directly; all DART-sourced figures were taken from aggregators (ETF Shopping, Valueline, Butler) that transcribe filings. The ISIN is derived from the KRX format and should be verified.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundOwnershipSource

Seo Hyun-jeong (서현정, Hyun Jeong Shu)

Representative Director (CEO)

Daughter of founder; special professor at Sangji University (appointed 2025); start date as CEO not disclosed in sources reviewed

403,986 shares, 5.42% (Oct 2025)

S1; S4; S7

Seo Jeong-gu (서정구)

Founder; Group Chairman (대한과학그룹 회장)

Founded the business in 1980; former researcher at Korea Minting and Security Printing Corporation

9.17% (FY2025)

S1; S5; S7

Seo Eun-taek (서은택)

Former CEO (c. 2012–2015)

Ex-Samsung Electronics; current role not confirmed

—

S5; S8

Lee Sang-beom (이상범)

CEO of a group affiliate

Listed among related parties

0.95%

S1

“—” = not publicly disclosed.

Directors' Remuneration

MetricFY2025Source

Average remuneration per director/auditor (KRW Mn)

120

S1

Number of directors/auditors in calculation

5

S1

Average employee salary (KRW Mn)

49.39

S1

Director-to-employee pay multiple (x)

2.4

S1

Major Shareholders

HolderRelationshipStake (%)Source / date

Seo Jeong-gu

Largest shareholder (founder)

9.17

S1, 31 Dec 2025

(주)싸이랩코리아 (Sci-Lab Korea)

Affiliate (DAIHAN owns 37.78%)

7.95

S1, 31 Dec 2025

Seo Hyun-jeong

Child; CEO

5.42

S1; S4

Seo Kang-min

Sibling

4.26

S1

Lee Hyun-sook

Spouse

3.45

S1

Lee Jae-woong

Nephew

3.06

S1

Lee Sang-beom

Affiliate CEO

0.95

S1

Lee Jae-ho

Spouse's nephew

0.83

S1

Choi Yoon-kyung

Nephew's spouse

0.83

S1

Seo Kang-woon

Sibling

0.36

S1

Lee Choong-hyung

Son-in-law

0.34

S1

Seo Kyung-taek

Nephew

0.34

S1

Founder and related parties, total

—

37.43

S1

Minority shareholders (13,438 holders)

—62.64

S1

Competitive Landscape

Competitors by Segment

Business lineCompetitorTypePositioning vs. DAIHANSource

Lab-equipment distribution (Korea)

Seoulin Bioscience (KOSDAQ 038070)

Listed distributor (bio-research equipment, reagents; healthcare)

Similar scale (FY2025 revenue KRW 77.1 B) but far lower margin; more life-science/omics oriented

S14; S1

Lab-equipment distribution (Korea)

Avantor / VWR

Global distributor and manufacturer

Global scale, private-label and e-commerce; relaunching VWR brand in 2026

S13

Lab-equipment distribution (Korea)

Thermo Fisher Scientific (Fisher Scientific channel)

Global leader

Dominant global scale; >12% global lab-equipment share

S12; S13

General lab instrument manufacturing (Korea)

JEIO Tech (제이오텍, Daejeon; private)

Domestic manufacturer of dryers, incubators, mixers, safety cabinets, reagent cabinets, medical refrigerators/freezers, chillers, reliability-test equipment

Closest domestic manufacturing rival; 2023 revenue KRW 57.7 B; ~295 employees

S14

General lab instrument manufacturing

Thermo Fisher (Heratherm, Forma, TSX freezers etc.)

Global

Premium brand in ovens, incubators, ULT freezers

S13

ULT and medical freezers

PHC (formerly Panasonic Healthcare), Eppendorf, Haier Biomedical, Thermo Fisher

Global

Global ULT freezer leaders

—

Stirrers, shakers, homogenizers

IKA, Heidolph, Eppendorf

Global (German)

Premium mixing equipment

—

Ovens and incubators

Memmert, Binder, Yamato Scientific

Global (German/Japanese)

Premium thermal equipment

—

Biosafety cabinets and fume hoods

Esco, Labconco, Thermo Fisher

Global

Safety-cabinet specialists

—

Analytical instruments (distribution)

Agilent, Danaher, Bruker, PerkinElmer (direct channels)

Global

Top-5 global lab-equipment players hold ~40% share

S12

Peer Comparison FY2025

MetricDAIHAN ScientificSeoulin BioscienceThermo Fisher ScientificAvantor

Fiscal year

FY2025

FY2025

FY2025

FY2025

Revenue

KRW 81.1 B

KRW 77.1 B

USD 44.56 B

USD 6.55 B

Revenue growth

+13.1%+2.2%

+4% (organic +2%)

−3.4% (organic −3%)

Operating margin

6.8%0.9%

17.4% (GAAP)

Not computed; adj. EBITDA margin 16.3%; GAAP net loss USD 530 M

R&D intensity

1.4%—

3.1% (USD 1.40 B)

—

Net income

KRW 4.8 B

KRW 0.6 B

—

−USD 530 M

Source

S1; S2

S14

S13

S13

Company Snapshot

$57.1M

Revenue

114

Employees

1980

Founded

Gangwon-do, South Korea

Headquarters

SWOT Analysis

Strengths

  • Record scale: FY2025 revenue of KRW 81.1 B (+13.1%) is the highest in company history, with growth continuing at +13.8% in Q2 2026 [S1].
  • Fortress balance sheet: borrowings fell from KRW 2.6 B (FY2022) to nil at June 2026; net cash KRW 15.9 B at FY2025 [S2].
  • Cash generation: FY2025 OCF KRW 5.4 B and FCF ~KRW 5.1 B against capex of only KRW 0.3 B [S2; S1].
  • Integrated model: combined manufacturing and distribution, described since 2012 as unique among Korean lab-equipment firms [S5].
  • Regulatory credentials: MFDS-certified ULT vaccine/blood freezer; GMP-certified medical devices; CE-certified mediclin™ consumables [S6].
  • Shareholder alignment: insider stake rising from 32.18% (2021) to 37.43% (2025); CEO open-market purchases Oct 2025 [S1; S4].
  • Dividend capacity: FY2025 DPS doubled to KRW 125 while payout stayed ~27% of owners' NI and ~18% of FCF [S1].

Weaknesses

  • Thin margins: operating margin 6.8% (FY2025) vs. 10.0% peak (FY2022) and 17.4% at Thermo Fisher [S1; S13].
  • Low R&D intensity: 1.4% of revenue (FY2025) [S2].
  • Working-capital intensity: cash conversion cycle ~169 days, inventory ~158 days (FY2025); inventory up a further 11% in H1 2026 [S2, analyst calc.].
  • Minority leakage: ~31% of FY2025 consolidated NI attributable to NCI; NCI equity KRW 11.8 B [S2].
  • Domestic concentration: ~89% domestic revenue (FY2025) [S2].
  • Earnings volatility: Q4 2025 OI fell 54% YoY on record revenue [S1].
  • Limited disclosure: no guidance, IR presentations, analyst coverage (0 reports per S15) or English-language reporting identified.

Opportunities

  • R&D budget upcycle: 2026 national R&D budget KRW 35.3–35.5 T, +19% YoY and +33% vs 2024 [S11].
  • Medical devices: company states Daihan Medical revenue is growing strongly each year; expanding GMP portfolio [S6].
  • Emerging-market exports: distributor network in Indonesia, Vietnam; Egyptian tender win [S6].
  • Global market growth: lab-equipment market growing ~5.9% CAGR, APAC 6.4% [S12].
  • Korean capital-market reforms: dividend-tax separation and value-up policies could reward high-payout, low-P/B stocks [Hankyung, Jul 2025, context]; DAIHAN trades at ~0.5x book.
  • Smart-lab/IoT: existing Smart-Lab and Wire platforms could be monetised as recurring services (no evidence yet).

Threats

  • Budget reversal risk: FY2024 showed revenue −2.7% and OI −32% when R&D budgets were cut [S1; S11].
  • Global competition: Thermo Fisher (USD 44.56 B revenue) and Avantor (relaunching VWR, upgrading e-commerce) [S13].
  • Domestic competition: JEIO Tech (~KRW 58 B revenue, ~295 staff) in own-brand instruments; Seoulin in distribution [S14].
  • FX: FY2025 FX losses KRW 0.73 B vs gains KRW 0.47 B on import-heavy mix [S2].
  • Supplier disintermediation: principals may go direct or switch distributors (risk inherent in 81% merchandise mix) [S3].
  • Labour-cost inflation: standalone payroll/revenue rose from 10.9% to 12.6% (FY2021–FY2025) [S1].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
20 Mar 2025FY2024 business report filed: revenue KRW 71.7 B (−2.7%), OI KRW 4.2 B (−32%), NI KRW 3.9 B S1Trough year aligned with national R&D cuts
20–23 Mar 2025KIMES 2025 participation (fourth consecutive year); GMP-certified devices exhibited S6Medical-device push
Mar 2025Order for six ultra-low freezers for an Egyptian military hospital reported S6Export validation of medical freezer line
11 Apr 2025FY2024 dividend paid, KRW 60/share S1Seventh year at KRW 60
15 May 2025Q1 2025: revenue KRW 15.7 B (+12.9%), OI KRW 0.9 B (+9.2%) S1Recovery begins
Jun 2025Industry–academia cooperation agreement with Sangji University S7Local partnership
Jul 2025Digital-healthcare social-contribution alliance MOU with Sangji University S7ESG / healthcare positioning
Jul 2025Vietnamese distributor at Medipharm Expo, Ho Chi Minh City (planned per company) S6Vietnam channel
14 Aug 2025H1 2025: Q2 revenue KRW 19.0 B (+7.9%), OI KRW 1.7 B (+87.5%) S1Operating leverage returns
22 Aug 2025Government proposes record KRW 35.3 T R&D budget for 2026 (+19.3%) S11Key demand driver for 2026
Oct 2025Indonesian distributor at Indonesia Hospital Expo, Jakarta (planned per company) S6SE Asia channel
16 & 22 Oct 2025CEO buys 6,360 shares (KRW 4,673–4,723); stake 5.42% S4Insider confidence signal
28 Oct 2025KRW 27.2 M lab-equipment donation to Sangji University; CEO appointed special professor S7Community / ESG
4 Nov 2025President's budget speech confirms KRW 35.3 T R&D proposal S11Policy confirmation
14 Nov 2025Q3 2025: revenue KRW 21.2 B (+15.0%), OI KRW 2.3 B (+98.2%), NI KRW 2.4 B S1Strongest quarterly profit of the cycle
Nov 2025MEDICA Düsseldorf participation (planned per company) S6European medical market
Dec 2025Medipharm Expo Hanoi participation (planned per company) S6Vietnam
Dec 20252026 national R&D budget finalised at ~KRW 35.5 T S11Demand tailwind
27 Feb 2026FY2025 dividend set at KRW 125 (+108%), ~KRW 0.9 B total S1Step-change in payout
19 Mar 2026FY2025 business report: record revenue KRW 81.1 B (+13.1%), OI KRW 5.5 B (+30.9%), NI KRW 4.8 B; Q4 OI KRW 0.6 B (−54%) S1Record top line; weak Q4 margin
10 Apr 2026FY2025 dividend paid S1Cash outflow; cash falls in Q2
15 May 2026Q1 2026: revenue KRW 17.6 B (+12.1%), OI KRW 1.0 B (+4.9%), NI KRW 0.9 B S1Growth sustained; modest leverage
30 Jun 2026Executive/major-shareholder ownership report and large-shareholding report filed S3–
21 Jul 2026Large-shareholding report filed S3As above
13 Aug 2026Large-shareholding report filed S3As above
14 Aug 2026H1 2026 report: Q2 revenue KRW 21.6 B (+13.8%), OI KRW 2.1 B (+22.1%), NI KRW 1.9 B (+30.7%); inventories KRW 28.2 B; cash KRW 3.4 B S1; S2Continued growth; inventory build
20 Oct 2026Shares close at KRW 3,430, near 52-week low (KRW 3,250); 1-year return −28.5% S1Valuation de-rating despite earnings growth

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 66,300 Mn in FY2021 to KRW 81,100 Mn in FY2025.
DAIHAN Scientific Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue66,30072,30073,70071,70081,100
Cost of sales47,80050,70051,50051,80058,700
Gross profit18,40021,60022,20019,90022,500

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.